It is made available under a CC-BY-ND 4.0 International license .

1 Prevalence of Chikungunya, Dengue, and West Nile arboviruses in Iran based on enzyme-linked

- 2 immunosorbent assay (ELISA): A systematic review and meta-analysis
- 3 Ebrahim Abbasi^{1, 2*}, Mohammad Djaefar Moemenbellah-Fard^{1, 2}
- 4 ¹*Research Center for Health Sciences, Institute of Health, Shiraz University of Medical Sciences,*
- 5 Shiraz, Iran
- 6 ²Department of Biology and Control of Disease Vectors, School of Health, Shiraz University of
- 7 Medical Sciences, Shiraz, Iran
- 8 * <u>abbasie.ebrahim@gmail.com</u>, <u>e_abbasie@sums.ac.ir</u>
- 9

10 Author Summary

Arboviruses, including Chikungunya (CHIKV), Dengue (DENV), and West Nile (WNV), pose significant health threats globally, with increasing infections reported, including in Iran. This report conducts a systematic review and meta-analysis of the seroprevalence of these viruses in Iran through ELISA testing. A total of twelve studies published from 2000 to 2024 were analyzed, revealing a seroprevalence of 12.9% for WNV and 6.2% for CHIKV, while DENV showed a mixed prevalence of 0% in one study and 5.6% in another. The results suggest that WNV and CHIKV are widespread in Iran, whereas DENV appears to be sporadic.

18

19 ABSTRACT

Introduction: Arboviruses, including Chikungunya (CHIKV), Dengue (DENV), and West Nile (WNV)
 viruses, are significant viral threats that affect numerous people globally each year. This report explores

the prevalence of these viruses in Iran through a systematic review and meta-analysis.

23 Methods: The present survey was performed with a systematic review and meta-analysis method on the

seroprevalence of WNV, CHIKV, and DENV using the ELISA test. Based on this, by search in Web of

25 Science, PubMed, Scopus, Cochrane Library, Science Direct, and Google Scholar scientific databases, all

relevant published papers were sorted out and reviewed. Power ratification of data was carried out with a

- 27 random effects model in meta-analysis, meta-regression, I^2 index, and Egger test.
- 28 **Results**: Twelve published papers between 2000 and 2024 were embodied in this meta-analysis report.

29 The seroprevalence of positive ELISA test for WNV in Iran was estimated at 12.9% (CI=95%: 7.4-18.4),

and for CHIKV at 6.2% (CI=95%: 0.6-11.8). Regarding DENV, only two studies were conducted with a

31 zero prevalence in one study, and a seroprevalence of 5.6% in another study.

32 Conclusion: According to these data, WNV, CHIKV, and DENV fevers have been detected in Iran using

33 ELISA test. Considering the seropositivity of WNV and CHIKV, and the finding of these viruses from

34 several provinces, it could be for granted that these two viruses are ubiquitous and DENV fever is

- 35 sporadic in Iran.
- 36 **Keywords:** Arbovirus, Chikungunya, Dengue, ELISA, Meta-analysis, Virus, WNV.
- 37

It is made available under a CC-BY-ND 4.0 International license .

38 Introduction

39 West Nile virus (WNV) is a single strand positive sense RNA virus in the Flaviviridae family, which is

40 mainly transmitted by *Culex* and *Aedes* mosquitoes. *Culex pipiens*, *Culex tarsalis*, and *Aedes vexans* are

41 the main vectors of WNV¹². In Iran, *Cx. pipiens* and *Ae. caspius* are vectors of WNV. Trans-ovarian

42 transmission of WNV among mosquito vectors is also possible, which renders them reservoirs of this

43 pathogen. WNV circulates between insects, birds, and mammals (as the dead-end host), and their life is

44 maintained in a cycle of "amplification" ². The virus cannot transfer between mammals, especially 45 humans to humans, and can only be transmitted to another person through organ transplants or blood

transfusions, and placental/ milk transmission. Accidental human infection is often ($\approx 80\%$) asymptomatic,

47 in 20% of cases with mild flu-like symptoms, and <1% can cause WNV neurotropic disease (WNND,

- 48 West Nile Neuro-invasive Disease), which usually occurs in elderly and immunocompromised
- 49 individuals, that can lead to death $^{3-6}$.

Migratory birds play important roles in the transmission and spread of WNV in the world, so today, this virus is prevalent in most parts of the world, including Europe and Asia. Since no effective and safe vaccine is available to deal with this virus ⁷, organizations and departments related to health have suggested that WNV monitoring plans be implemented in the form of collecting virologic, entomologic, veterinary, and epidemiologic data to monitor the spread of WNV, and identify cases of human infection so that prevention, control, and adoption of appropriate treatment protocols to deal with this virus could be undertaken ⁸⁻¹⁰.

Dengue virus (DENV) is also a single strand positive sense RNA virus in the Flaviviridae family, and the 57 causative agent of the newly-emergent dengue fever which has four serotypes 1, 2, 3, and 4^{11} . The 58 primary and secondary vectors of DENV are Aedes aegypti and Aedes albopictus mosquitoes ¹². Trans-59 ovarian transmission of DENV among vectors is possible. The life of all four DENV serotypes is 60 maintained in two sylvatic and urban cycles. The Asian tiger mosquito, Ae. albopictus, serves as a 61 "bridge" vector between these two cycles. Both these diurnally-active anthropophilic Aedes vectors are 62 63 increasingly reported from SE Iran. In the sylvatic cycle, the virus is transmitted from non-human mammals to mosquitoes, and then to mammals, such as the monkey-Aedes-monkey cycle, which is 64 ecologically and evolutionarily distinct from the human transmission cycle¹³. 65

More than 400 million infections, and >20,000 deaths occur annually due to DENV worldwide ^{11 14}. This 66 disease often exists as a latent or asymptomatic infection, and in endemic/ epidemic forms in different 67 regions of the world ¹¹. Low-to-medium viremia in these persons could be infectious to mosquitoes. The 68 continents of Asia, America, Africa, and Australia witness DENV epidemics every year ¹⁵. Clinical 69 70 manifestations of dengue infection range from mild fever to severe dengue hemorrhagic fever (DHF). 71 Infection with one serotype of DENV can provide lifelong immunity to the same serotype, while 72 secondary infection with other serotypes levitates the risk of infection to severe DENV. No effective 73 vaccine is available for this virus ¹⁶.

74 Chikungunya virus (CHIKV) is a single strand positive sense RNA virus of the alphavirus genus in 75 Togaviridae family. Alphaviruses can cause inflammatory musculoskeletal diseases with debilitating 76 symptoms such as arthritis, arthralgia, and myalgia in humans¹⁷. CHIKV is transmitted by *Aedes*

mosquitoes, especially *furcifer*, *africanus*, *aegypti*, *albopictus*, and *Stegomyia* species 18 . This virus has

three genotypes, namely West Africa (WA), East/Central/Southern Africa (ECSA), and Asian. All three

It is made available under a CC-BY-ND 4.0 International license .

- genotypes are distributed worldwide, but ECSA and Asian genotypes are more common ¹⁹⁻²¹. The virus is 79
- 80 maintained in a rural enzootic transmission cycle or the sylvatic cycle between Aedes mosquitoes and
- animal reservoirs. However, today the virus has adapted to urban cycles, and no longer requires the 81
- presence of non-human primates or the sylvatic cycle for their maintenance 22 . 82

Unlike DENV, CHIKV is not life threatening. Mortality caused by this virus is low, but it can cause 83 84 severe complications, and affect people's quality of life. In most cases, CHIKV infection presents with a 85 sudden onset of fever accompanied by joint pain. In minor cases, it leads to polyarthralgia and debilitating arthritis, rashes, myalgia, and headache²³. Asymptomatic infection is rare and occurs in 3-28% of cases in 86 epidemics ^{24 25}. The infection is often self-limiting, and the patient eventually recovers, but some patients 87 develop persistent joint pain that may persist for months or years after the acute stage of the disease ^{26 27}. 88 Approximately 30-40% of infected individuals experience some long-term complications ²⁸. So far, no 89

- vaccine is available to prevent this virus ¹⁸. 90
- 91 ELISA (Enzyme-linked immunosorbent assay) test is a method of serological examination of viruses in 92 the world. Due to its high sensitivity, and low false positive rate of about 20%, this test is recommended 93 as a serological test for the initial screening of viral diseases. The presence of DENV IgG antibodies in people indicates that they have been infected with the virus in the past or present, which is usually 94
- 95 investigated in the ELISA test²⁹.
- 96 Due to the lack of an effective vaccine to prevent viral infections of arboviruses and the existence of 97 complications and death caused by these viruses, awareness of the prevalence, distribution, and detection
- 98 methods of these viruses to adopt control and prevention programs is essential. The named viral diseases
- 99
- have been known in Iran in the past years. However, their prevalence is different in different regions of 100 Iran. Accordingly, this study was conducted to determine the positive rate of ELISA test for WNV,
- DENV, and CHIKV by a systematic review and meta-analysis method in Iran, to achieve comprehensive 101
- 102 results regarding the spread of these viruses.

103 **Materials and Methods**

104 Study Protocol

This study was conducted by the method of systematic review and meta-analysis in the field of ELISA 105

tests for the three arboviruses of WNV, CHIKV, and DENV based on the guidelines of PRISMA 106 107 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)³⁰.

Search Strategy 108

- 109 In the initial search, all English-language articles published from the beginning of 2000 to the end of May
- 110 2024 were extracted by searching the Web of Science, PubMed, Scopus, Cochrane Library, Science
- 111 Direct, and Google Scholar databases. Search for articles using the keywords Arbovirus, West Nile Virus,
- West Nile Virus Infection, WNV, West Nile Virus IgG, IgG anti-WNV, Dengue Fever, Dengue virus, 112
- Dengue virus infection, Chikungunya virus, Enzyme-linked immunosorbent assay, ELISA, Serology, 113
- Seroprevalence, Seropositivity, Iran, Iranian in the title, abstract and keywords were done in singular and 114
- 115 compound form using "AND" and "OR" operators.

Inclusion and Exclusion Criteria 116

It is made available under a CC-BY-ND 4.0 International license .

- All the English-language articles published in Iran were in the field of arboviruses: WNV, CHIKV, and 117
- 118 DENV. The serological examination of the virus was done using the ELISA test, the positive rate of
- ELISA test was reported with good quality. These were entered into the study. Articles that did not meet 119
- the inclusion criteria or were conducted using meta-analysis, review, case report, or case series methods 120
- 121 were excluded from the study.

122 **Quality Assessment**

The quality assessment of the articles was done based on 22 parts of the STROBE (Strengthening the 123 124 Reporting of Observational Studies in Epidemiology) checklist, which examined compliance with the 125 principles of writing and implementation in the title, the method of reporting findings, limitations, and 126 conclusions. Each part of this checklist is given a score based on its importance, and the maximum possible score is 33^{31} . 127

128 Screening and Data Extraction

129 The articles were screened by two researchers independently by examining the title and abstract of the

- articles and considering the inclusion and exclusion criteria. Finally, the full text of the articles was 130 investigated by two researchers independently, and if the articles were rejected by two people, the reason 131
- 132
- was mentioned, and in case of disagreement between them, the article was refereed by a third person. 133 Data extraction was done using a pre-prepared checklist that included study location, study time, sample
- 134 size, type of serological test, number of positive ELISA tests, and type of virus under investigation.

135 **Study Selection**

- 136 In the initial search and considering the inclusion criteria, 794 articles were extracted. Then, using the
- Endnote software, the duplication of sources was investigated, and 259 articles were excluded from the 137
- study due to duplication. Then, by investigating the titles and summaries of the articles, 486 articles were 138
- excluded from the study due to their irrelevance. After reviewing the full text of the articles, 37 articles 139
- were excluded due to the lack of investigation on the prevalence of the ELISA test and the unknown 140
- 141 population. Finally, 12 articles entered the meta-analysis process (Figure 1).

142 Statistical Analysis

- 143 In order to combine the results in heterogeneous studies, random-effects model was used, and in the 144 homogeneous studies, the fixed-effects model in meta-analysis was deployed. To investigate the heterogeneity of the data, I^2 and Cochrane Q tests were used. Publication bias was controlled by Egger
- 145 146 test, and funnel plot and data analysis were performed using STATA ver. 17.0 software.

147 Results

- Overall, 12 articles that were conducted in Iran between 2010 and 2023 were included in this meta-148 analysis process. Nine articles on WNV^{29 32-39}, three articles on CHIKV^{38 40 41}, and two articles on DENV
- 149 ^{29 42} were scrutinized. The characteristics of the articles included in the meta-analysis are presented in 150
- 151 Table 1.
- Nine articles with a sample size of 3013 people in the field of WNV serology in Iran were included in the 152
- meta-analysis process. Based on these findings, the prevalence of WNV was estimated to be 12.9% using 153
- the ELISA serology test in Iran. Among the surveyed studies, the highest prevalence of WNV positive 154
- 155 tests was related to that conducted in Fars province with a prevalence of 27.3%, and the lowest prevalence
- 156 of the test related to the studies carried out in Golestan, Gilan, and Qom provinces with a prevalence of
- 157 1.3% (Figure 2).

It is made available under a CC-BY-ND 4.0 International license .

158 The meta-analysis of three studies performed on the prevalence of positive CHIKV assay in Iran showed

that 6.2% of the studied population had a positive ELISA test in this regard (Figure 3). The prevalence of

160 positive Dengue fever virus ELISA test in Iran was also investigated in two studies. In one survey 42 ,

- there was no case of positive ELISA test in the field of DENV, while the prevalence of this virus was
- 162 reported at 5.6% in the other study 43 conducted in Sistan-Baluchistan province 2943 .

163 The publication bias was evaluated using a funnel plot and Egger test. Considering the symmetry of the 164 funnel plot and the fact that the studies with a high sample size are placed under the plot, it can be 165 mentioned that the publication bias did not occur (P = 0.12) (Figure 4). Although several studies with a 166 smaller sample size are outside the graph, it shows that to make a general consensus, it is necessary to 167 conduct another series of studies in this field. Investigating the prevalence of positive ELISA tests based 168 on the current sample volumes showed that with the increase in sample size, the prevalence of positive 169 ELISA tests has also increased (Figure 5).

170 Discussion

171 Based on the findings of this meta-analysis using the ELISA serology test in Iran, the WNV prevalence was estimated to be 12.9% (95%, CI: 18.4-7.4). In the past decades, WNV has spread in most regions of 172 the world, which has affected its virulence, pathogenicity, epidemiology, and hosts. WNV has caused 173 major epidemics with thousands of human morbidity cases and mortality in the world ⁴⁴. This virus is 174 175 endemic in the Middle East, in the countries of Pakistan, Jordan, Turkey, Iraq, Oman, Saudi Arabia, Sudan, Yemen, Egypt and Afghanistan⁴⁵⁻⁴⁷. The prevalence of WNV was 26.6% in Pakistan, 30.4% in 176 Afghanistan, and 10.4% in Qatar ^{48 49}. In Iraq (11.6-15.1%), Egypt (1-61%), Jordan (8%), Iran (0-30%), 177 Libva (2.3%), Lebanon (0.5-1%), Pakistan (0.6-65.0%), Morocco (0-18.8%), Tunisia (4.3-31.1%), and 178 Sudan (2.2-47%) have been reported 50 . 179

180 The WNV virus is ubiquitously endemic in Iran. Various factors, including weather conditions such as 181 temperature and relative humidity fluctuations, can affect the activity of this virus vector, as a result, its prevalence varies in different regions of the country ⁵¹. In general, the prevalence of WNV in Iran is close 182 to the endemic areas and neighboring countries of Iran. According to the results of surveys included in 183 this meta-analysis process, the prevalence of this virus in the southern provinces was higher than in the 184 185 northern and western provinces of Iran, which can be related to the increased amplification of its virus vectors in the south, and neighboring countries of Iran, which have a higher prevalence of this virus. In 186 187 general, the prevalence of WNV in Iran is relatively high, and it is necessary to evaluate the circulation of 188 this virus in Iran every year, and implement preventive measures to mitigate the spread of this virus in the 189 country.

190 The results of meta-analysis on the prevalence of positive ELISA test for CHIKV showed that this virus prevalence was 6.2% (95%, CI: 0.6-11.8) in Iran. Studies have shown that the prevalence of CHIKV 191 varies in different regions of the world. Its epidemics occur every 7-8-year period. The CHIKV is not life-192 193 threatening in contrast to DENV. The prevalence of CHIKV has been reported in Italy as 10.2% ⁵², in India as 22.3% ⁵³, in Tanzania as 3.7% ⁵⁴ and in Turkey as 0.4% ⁵⁵. Also, the presence of CHIKV has 194 been reported only in Saudi Arabia, Pakistan, Sudan, Yemen, Somalia, Egypt, Oman, Iraq, and Kuwait, 195 and is known to be endemic in many parts of these regions ^{8 56}. In general, it can be mentioned that this 196 disease has a relatively high prevalence in Iran, and Iran can be considered as an endemic region for 197 CHIKV. Although this disease causes more complications to people, and its attenuation is relatively low, 198

It is made available under a CC-BY-ND 4.0 International license .

199 knowing its prevalence is essential for control programs. Based on this, it is necessary to assess and 200 monitor the serological prevalence of this virus annually.

201 With regard to Dengue fever virus (DFV), only one study which was conducted in Sistan-Baluchistan, the

prevalence of this virus was 5.6% ⁴³. Other studies were conducted in the form of reports of Dengue fever in Tehran (2012 and 2009) ^{57 58}, and it showed that this virus was detected in different years in Iran. But apart from the SE regions of Iran, it has occurred sporadically in other regions. It should be noted that most of these cases were often reported as imported cases.

- 206 Dengue fever is recognized as a disease in developing countries of SE Asia, and most cases occur in these countries ⁵⁹. Pakistan, Yemen, Saudi Arabia, Madagascar, and Sudan are among the countries where 207 dengue fever is reported as endemic ⁶⁰. In India, the prevalence of dengue fever is 23%, and in Sudan, it is 208 47.6% ^{61 62}. These countries and SE Asian countries are often considered tourist destinations for Iranians, 209 and many people from Iran travel to these countries every year. As a result, the possibility of contracting 210 DFV, and transferring it inside the country increases, especially among travelers returning from Saudi 211 Arabia following pilgrimage ^{57 63}. In general, it can be mentioned that cases identified in other provinces 212 of Iran, except Sistan-Baluchistan, can be imported cases from other countries, and often occur 213 214 sporadically.
- Approximately, 3.9 billion people in 129 countries are at risk of contracting DENV worldwide. Almost
- 70% of this global burden of DENV is related to Asia. According to World Health Organization (WHO),
 DENV cases have levitated more than eight times in the last two decades. Several important outbreaks of
- DENV cases have revitated more than eight times in the last two decades. Several important outbreaks of
- 218 DENV have recently happened in the Eastern Mediterranean Regional Organization (EMRO) countries, 219 including Saudi Arabia, Yemen, Oman, Sudan, and Pakistan. Alarmingly, asymptomatic humans despite
- including Saudi Arabia, Yemen, Oman, Sudan, and Pakistan. Alarmingly, asymptomatic humans despite
 low-medium level of viremia transmit DENV to vector mosquitoes ⁶⁴. The inter-epidemic period for
- 221 DENV is 3-5 years.
- 222 The main anthropophilic vector, Aedes aegypti, of DENV is a diurnally-active endophilic species. After
- seven decades, this mosquito species has re-emerged, particularly in the coastal SE region of Iran. There
- are also unconfirmed reports of *Aedes albopictus* presence in the same Oriental provinces of this country.
- 225 Pregnant females and immunocompromised individuals, like those with diabetes, allergies, and many
- 226 chronic diseases, are specially at risk of being afflicted with DENV.

227 Conclusions

Based on the present systematic review and meta-analysis findings, WNV, CHIKV, and DENV have been detected in Iran using ELISA test. Considering the prevalence of WNV and CHIKV, and also the identification of these viruses in several provinces, it could be postulated that these two viruses are endemic in Iran, while DENV occurs sporadically in Iran. Based on this, to monitor and surveil the spread and outbreak of these viruses, it is recommended to screen suspected travelers and high-risk cohorts from highly-endemic neighborhood regions using the ELISA test combined with the more sophisticated molecular tools such as polymerase chain reactions (PCR).

(*N.B.* While this MS was under the submission process, three new fatal cases of DENV were reportedfrom the SE counties of Fars and Hormozgan provinces, Iran).

- 237
- 238 **DECLARATIONS**

It is made available under a CC-BY-ND 4.0 International license .

239 Funding

240 No funding was received for this manuscript.

241 Ethical Approval

242 Not applicable. No ethical approval is applicable since it is a review article.

243 Conflict of Interests

244 The authors declare no conflict of interests.

245 Data Availability and Materials

The data that support the findings of this study are available from the corresponding author upon reasonable request

248 Acknowledgments

- 249 The authors wish to convey their appreciation to the Vice-Chancellor for Research and Technology at
- 250 Shiraz University of Medical Sciences (SUMS) for provision of software support and other logistics. This
- 251 meta-analysis report was part of a self-initiative attempt to screen and elucidate the current status of three
- highly-important clinical arboviruses in Iran, forming a basis to the part fulfilment of a PhD thesis by
- E.A. under the supervisorship of M.D.M-F. in the Dept. of Biology and Control of Disease Vectors,
- 254 School of Health, Shiraz, Iran.

255

It is made available under a CC-BY-ND 4.0 International license .

256 **References**

- García-Carrasco J-M, Muñoz A-R, Olivero J, et al. Predicting the spatio-temporal spread of West Nile
 virus in Europe. *PLoS neglected tropical diseases* 2021;15(1):e0009022.
- 2. Riccò M, Peruzzi S, Balzarini F. Epidemiology of West Nile virus infections in humans, Italy, 2012–
 2020: a summary of available evidences. *Tropical Medicine and Infectious Disease* 2021;6(2):61.
- 3. Stonedahl S, Clarke P, Tyler KL. The role of microglia during West Nile virus infection of the central nervous system. *Vaccines* 2020;8(3):485.
- 4. Habarugira G, Suen WW, Hobson-Peters J, et al. West Nile virus: an update on pathobiology, epidemiology, diagnostics, control and "one health" implications. *Pathogens* 2020;9(7):589.
- 5. Yu A, Ferenczi E, Moussa K, et al. Clinical spectrum of west nile virus neuroinvasive disease. *The Neurohospitalist* 2020;10(1):43-47.
- 267 6. Sejvar J. Clinical Manifestations and Outcomes of West Nile Virus Infection. *Viruses* 2014;6:606-23.
 268 doi: 10.3390/v6020606
- 7. Kaiser J, Barrett A. Twenty Years of Progress Toward West Nile Virus Vaccine Development. 2019
 5(9):823. doi: doi: 10.3390/v11090823. PMID: 31491885; PMCID: PMC6784102
- 8. Tamba M, Bonilauri P, Galletti G, et al. West Nile virus surveillance using sentinel birds: results of
 eleven years of testing in corvids in a region of northern Italy. *Frontiers in Veterinary Science*2024;11:1407271.
- 9. Moirano G, Richiardi L, Calzolari M, et al. Recent rapid changes in the spatio □ temporal distribution of
 West Nile Neuro □ invasive Disease in Italy. *Zoonoses and public health* 2020;67(1):54-61.
- 10. Moirano G, Gasparrini A, Acquaotta F, et al. West Nile Virus infection in Northern Italy: Case crossover study on the short-term effect of climatic parameters. *Environmental Research* 2018;167 doi: 10.1016/j.envres.2018.08.016
- 279 11. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature* 2013;496(7446):504-07.
- 12. Carrington LB, Simmons CP. Human to mosquito transmission of dengue viruses. *Frontiers in immunology* 2014;5:86757.
- 13. Chen R, Vasilakis N. Dengue—quo tu et quo vadis? *Viruses* 2011;3(9):1562-608.
- 14. Shepard DS, Undurraga EA, Halasa YA, et al. The global economic burden of dengue: a systematic
 analysis. *The Lancet infectious diseases* 2016;16(8):935-41.
- 15. Wu W, Bai Z, Zhou H, et al. Molecular epidemiology of dengue viruses in southern China from 1978 to 2006. *Virology journal* 2011;8:1-9.
- 16. Wahala WM, De Silva AM. The human antibody response to dengue virus infection. *Viruses* 289 2011;3(12):2374-95.
- 17. Ferreira JM, Dutra JCV, dos Santos BRC, et al. Arboviruses (Alphavirus) related to autoimmune
 rheumatic diseases: Triggers and possible therapeutic interventions. Translational Autoimmunity:
 Elsevier 2023:543-64.
- 18. de Lima Cavalcanti TYV, Pereira MR, de Paula SO, et al. A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. *Viruses* 2022;14(5):969.
- 19. Wahid B, Ali A, Rafique S, et al. Global expansion of chikungunya virus: mapping the 64-year
 history. International journal of infectious diseases : IJID : official publication of the
 International Society for Infectious Diseases 2017;58:69-76. doi: 10.1016/j.ijid.2017.03.006
 [published Online First: 2017/03/16]
- 20. Ferreira FCPdADM, da Silva ASV, Recht J, et al. Vertical transmission of chikungunya virus: A
 systematic review. *PLoS One* 2021;16(4):e0249166.
- Agarwal A, Dash PK, Singh AK, et al. Evidence of experimental vertical transmission of emerging
 novel ECSA genotype of Chikungunya Virus in Aedes aegypti. *PLoS Negl Trop Dis* 2014;8(7):e2990. doi: 10.1371/journal.pntd.0002990 [published Online First: 2014/08/01]
- 22. Diallo D, Sall AA, Buenemann M, et al. Landscape ecology of sylvatic chikungunya virus and mosquito vectors in southeastern Senegal. *PLoS Negl Trop Dis* 2012;6(6):e1649. doi: 10.1371/journal.pntd.0001649 [published Online First: 2012/06/22]

- 307 23. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and
 308 prospective intervention strategies. *The Journal of clinical investigation* 2017;127(3):737-49. doi:
 309 10.1172/jci84417 [published Online First: 2017/03/02]
- 24. Appassakij H, Khuntikij P, Kemapunmanus M, et al. Viremic profiles in asymptomatic and
 symptomatic chikungunya fever: a blood transfusion threat? *Transfusion* 2013;53(10 Pt 2):256774. doi: 10.1111/j.1537-2995.2012.03960.x [published Online First: 2012/11/28]
- 25. Cunha RVD, Trinta KS. Chikungunya virus: clinical aspects and treatment A Review. *Memorias do Instituto Oswaldo Cruz* 2017;112(8):523-31. doi: 10.1590/0074-02760170044 [published Online
 First: 2017/08/03]
- 26. Tritsch SR, Encinales L, Pacheco N, et al. Chronic Joint Pain 3 Years after Chikungunya Virus
 Infection Largely Characterized by Relapsing-remitting Symptoms. *The Journal of rheumatology* 2020;47(8):1267-74. doi: 10.3899/jrheum.190162 [published Online First: 2019/07/03]
- 27. Chang AY, Encinales L, Porras A, et al. Frequency of Chronic Joint Pain Following Chikungunya
 Virus Infection: A Colombian Cohort Study. *Arthritis & rheumatology (Hoboken, NJ)* 2018;70(4):578-84. doi: 10.1002/art.40384 [published Online First: 2017/12/22]
- 22. Murillo-Zamora E, Mendoza-Cano O, Trujillo-Hernández B, et al. Persistent arthralgia and related
 risks factors in laboratory-confirmed cases of Chikungunya virus infection in Mexico. *Revista Panamericana de Salud Pública* 2017;41:e72.
- 29. Aghaie A, Aaskov J, Chinikar S, et al. Frequency of West Nile virus infection in Iranian blood
 donors. *Indian Journal of Hematology and Blood Transfusion* 2016;32:343-46.
- 30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta analysis protocols (PRISMA-P) 2015 statement. *Systematic reviews* 2015;4(1):1.
- 31. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in
 Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International journal of surgery* 2014;12(12):1495-99.
- 332 32. Amin M, Zaim M, Edalat H, et al. Seroprevalence study on West Nile virus (WNV) infection, a
 hidden viral disease in fars province, southern Iran. *Journal of Arthropod-Borne Diseases* 2020;14(2):173.
- 335 33. Babahajian A, Sharifi P, Babahajiani W, et al. Seroprevalence of West Nile Virus in Regular Blood
 336 Donors Referred to the Blood Bank of Kurdistan Province, Iran. Sudan Journal of Medical
 337 Sciences 2022;17(2):192-203.
- 338 34. Chinikar S, Shah-Hosseini N, Mostafavi E, et al. Seroprevalence of west nile virus in iran. *Vector-* 339 *Borne and Zoonotic Diseases* 2013;13(8):586-89.
- 340 35. Kalantari M, Salehi-Vaziri M, Pouriayevali MH, et al. Seroprevalence of West Nile virus in
 341 Khuzestan province, southwestern Iran, 2016–2017. Journal of Vector Borne Diseases
 342 2019;56(3):263-67.
- 36. Meshkat Z, Chinikar S, Shakeri M, et al. Prevalence of West Nile virus in Mashhad, Iran: A
 population–based study. *Asian Pacific journal of tropical medicine* 2015;8(3):203-05.
- 345 37. Sharifi Z, MAHMOUDIAN SM, Talebian A. A study of West Nile virus infection in Iranian blood
 346 donors. 2010
- 347 38. Solgi A, Karimi A, Armin S. Seropositivity of chikungunya and West Nile viruses in Iranian children
 348 in 2018. Archives of Pediatric Infectious Diseases 2020;8(2)
- 349 39. Ziyaeyan M, Behzadi MA, Leyva-Grado VH, et al. Widespread circulation of West Nile virus, but not
 350 Zika virus in southern Iran. *PLoS Neglected Tropical Diseases* 2018;12(12):e0007022.
- 40. Pouriayevali MH, Rezaei F, Jalali T, et al. Imported cases of Chikungunya virus in Iran. BMC
 Infectious Diseases 2019;19:1-8.
- 41. Poudine M, Parsi-Moud A, Mohagheghi-Fard AH, et al. Seroprevalence of Chikungunya Virus
 Infection in Sistan and Baluchestan Province, Iran: A Pilot Study. Archives of Clinical Infectious
 Diseases 2023;18(6)
- 42. Khalili M, Aflatoonian MR, Hemati M, et al. Dengue fever serology in febrile patients in Southeast
 Iran. *Journal of Kerman University of Medical Sciences* 2019;26(1):90-94.

- 43. Aghaie A, Aaskov J, Chinikar S, et al. Frequency of dengue virus infection in blood donors in Sistan
 and Baluchestan province in Iran. *Transfus Apher Sci* 2014;50(1):59-62. doi:
 10.1016/j.transci.2013.07.034 [published Online First: 2013/12/18]
- 44. Sotelo E, Gutierrez-Guzmán AV, del Amo J, et al. Pathogenicity of two recent Western
 Mediterranean West Nile virus isolates in a wild bird species indigenous to Southern Europe: the
 red-legged partridge. *Veterinary Research* 2011;42:1-8.
- 45. Wallace MR, Hale BR, Utz GC, et al. Endemic infectious diseases of Afghanistan. *Clinical Infectious Diseases* 2002;34(Supplement_5):S171-S207.
- 46. Kalaycioglu H, Korukluoglu G, Ozkul A, et al. Emergence of West Nile virus infections in humans in
 Turkey, 2010 to 2011. *Eurosurveillance* 2012;17(21):20182.
- 47. Humphrey JM, Al-Absi ES, Hamdan MM, et al. Dengue and chikungunya seroprevalence among
 Qatari nationals and immigrants residing in Qatar. *PloS one* 2019;14(1):e0211574.
- 48. Khan E, Barr KL, Farooqi JQ, et al. Human West Nile virus disease outbreak in Pakistan, 2015–2016.
 Frontiers in public health 2018;6:20.
- 49. Elyan DS, Moustafa L, Noormal B, et al. Serological evidence of Flaviviruses infection among acute
 febrile illness patients in Afghanistan. *The Journal of Infection in Developing Countries* 2014;8(09):1176-80.
- 50. Eybpoosh S, Fazlalipour M, Baniasadi V, et al. Epidemiology of West Nile Virus in the Eastern
 Mediterranean region: A systematic review. *PLoS neglected tropical diseases* 2019;13(1):e0007081.
- 51. Platonov AE, Fedorova MV, Karan LS, et al. Epidemiology of West Nile infection in Volgograd,
 Russia, in relation to climate change and mosquito (Diptera: Culicidae) bionomics. *Parasitology research* 2008;103:45-53.
- 52. Moro ML, Gagliotti C, Silvi G, et al. Chikungunya virus in North-Eastern Italy: a seroprevalence
 survey. *The American journal of tropical medicine and hygiene* 2010;82(3):508.
- 53. Balasubramaniam SM, Krishnakumar J, Stephen T, et al. Prevalence of chikungunya in urban field
 practice area of a private medical college, Chennai. *Indian Journal of Community Medicine* 2011;36(2):124-27.
- 54. Kajeguka DC, Kaaya RD, Mwakalinga S, et al. Prevalence of dengue and chikungunya virus
 infections in north-eastern Tanzania: a cross sectional study among participants presenting with
 malaria-like symptoms. *BMC infectious diseases* 2016;16:1-9.
- 55. Atalay T, Kaygusuz S, Azkur AK. A study of the chikungunya virus in humans in Turkey. *Turkish Journal of Medical Sciences* 2017;47(4):1161-64.
- 56. Humphrey JM, Cleton NB, Reusken CB, et al. Urban chikungunya in the Middle East and North
 Africa: a systematic review. *PLoS neglected tropical diseases* 2017;11(6):e0005707.
- 57. Chinikar S, Ghiasi S, Moradi M, et al. Laboratory detection facility of dengue fever (DF) in Iran: the
 first imported case. *Int J Infect Dis* 2010;8(1):1-2.
- 58. Mardani M, Abbasi F, Aghahasani M, et al. First Iranian imported case of dengue. *International journal of preventive medicine* 2013;4(9):1075.
- 397 59. Wilder-Smith A, Chen LH, Massad E, et al. Threat of dengue to blood safety in dengue-endemic
 398 countries. *Emerging infectious diseases* 2009;15(1):8.
- 60. Guzman MG, Halstead SB, Artsob H, et al. Dengue: a continuing global threat. *Nature reviews microbiology* 2010;8(Suppl 12):S7-S16.
- 401 61. Eldigail MH, Adam GK, Babiker RA, et al. Prevalence of dengue fever virus antibodies and
 402 associated risk factors among residents of El-Gadarif state, Sudan. *BMC public health* 2018;18:1403 8.
- Kumar M, Verma RK, Mishra B. Prevalence of dengue fever in Western Uttar Pradesh, India: a
 gender-based study. *International Journal of Applied and Basic Medical Research* 2020;10(1):811.
- 407 63. Wiwanitkit V. Non vector-borne transmission modes of dengue. *Journal of Infection in Developing* 408 *Countries* 2010;4(1)

It is made available under a CC-BY-ND 4.0 International license .

409 410 411	64. Duong V, Lambrechts L, Paul RE, et al. Asymptomatic humans transmit dengue virus to mosquitoes. <i>Proc Natl Acad Sci U S A</i> 2015;112(47):14688-93. doi: 10.1073/pnas.1508114112 [published Online First: 2015/11/11]
412	
413	
414	
415	
416	
417	List of Legends
418	Fig 1. The review process based on PRISMA flow chart.
419 420 421 422	Fig 2 . Pooled prevalence of positive ELISA test for West Nile virus in Iran based on the random effects model. The midpoint of each line segment shows the prevalence estimate, the length of the line segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled prevalence.
423 424 425 426	Fig 3 . Pooled prevalence of positive ELISA test for Chikungunya virus in Iran based on random effects model. The midpoint of each line segment shows the prevalence estimate, the length of the line segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled prevalence.
427	Fig 4. Funnel plot of the prevalence positive ELISA test in the selected studies.
428	Fig 5. Meta-regression plot of prevalence of West Nile virus and sample size of study.
429	
430	
431	
432	
433	
434	
435	
436	

It is made available under a CC-BY-ND 4.0 International license .

- 437
- 438

439 Figure legend



It is made available under a CC-BY-ND 4.0 International license .



Figure 2. Pooled prevalence of positive ELISA test for West Nile virus in Iran based on the random effects model. The midpoint of each line segment shows the prevalence estimate, the length of the line segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled prevalence.

It is made available under a CC-BY-ND 4.0 International license .



475

476 Figure 3. Pooled prevalence of positive ELISA test for Chikungunya virus in Iran based on random 477 effects model. The midpoint of each line segment shows the prevalence estimate, the length of the line 478 segment indicates the 95% confidence interval in each study, and the diamond mark illustrates the pooled 479 prevalence.

480

481

It is made available under a CC-BY-ND 4.0 International license .





Figure 4. Funnel plot of the prevalence positive ELISA test in the selected studies.

It is made available under a CC-BY-ND 4.0 International license .



It is made available under a CC-BY-ND 4.0 International license .

496 Table legends

Table 1. Characteristics of the articles included in the meta-analysis

	Place of study	Year of publication	Sample Size	Type of virus	Type of
Author (ref.)				• •	serological
					test
Sharifi Z ³⁷	Tehran	2010	500	WNV	ELISA
Meshkat Z ³⁶	Mashhad	2015	182	WNV	ELISA
Aghaie A ²⁹	Chabahar	2016	540	WNV and DENV	ELISA
Solgi A ³⁸	Tehran	2020	180	WNV and CHIKV	ELISA
Chinikar S ³⁴	Golestan, Qom and Gilan	2013	300	WNV	ELISA
Babahajian A ³³	Kurdistan	2022	259	WNV	ELISA
Amin M ³²	Fars	2020	150	WNV	ELISA
Kalantari M ³⁵	Khuzestan	2019	408	WNV	ELISA
Ziyaeyan M ³⁹	Hormozgan	2018	494	WNV	ELISA
Khalili M ⁴²	Sistan-Baluchistan, Kerman and South Khorasan	2019	184	DENV	ELISA
Pouriayevali MH ⁴⁰	Sistan-Baluchistan	2019	151	CHIKV	ELISA
Poudine M ⁴¹	Sistan-Baluchistan	2023	203	CHIKV	ELISA